Results 31 to 40 of about 9,355,841 (357)

Forecasting the progression of Alzheimer's disease using neural networks and a novel preprocessing algorithm

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Introduction There is a 99.6% failure rate of clinical trials for drugs to treat Alzheimer's disease, likely because Alzheimer's disease (AD) patients cannot be easily identified at early stages. This study investigated machine learning approaches to use
Jack Albright, Alzheimer's Disease Neuroimaging Initiative   +1 more
doaj   +1 more source

EEG UPPER/LOW ALPHA FREQUENCY POWER RATIO RELATES TO TEMPORO-PARIETAL BRAIN ATROPHY AND MEMORY PERFORMANCES IN MILD COGNITIVE IMPAIRMENT

Frontiers in Aging Neuroscience, 2013
Objective: temporo-parietal cortex thinning is associated to mild cognitive impairment (MCI) due to Alzheimer disease (AD). The increase of EEG upper/low alpha power ratio has been associated with AD-converter MCI subjects.
Davide Vito Moretti, donata epaternicò, Giuliano eBinetti, Orazio eZanetti, giovanni b Frisoni   +4 more
doaj   +1 more source

Accelerating diversity in Alzheimer's disease research by partnering with a community advisory board

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023
Introduction Community advisory boards (CABs) and researcher partnerships present a promising opportunity to accelerate enrollment of underrepresented groups (URGs).
Alex Pena‐Garcia, Ralph Richards, Mollie Richards, Christopher Campbell, Hank Mosley, Joseph Asper, Johanne Eliacin, Angelina Polsinelli, Liana Apostolova, Hugh Hendrie, Andrew Tackett, Caprice Elliott, Sarah Van Heiden, Sujuan Gao, Andrew Saykin, Sophia Wang, IADRC CAB   +16 more
doaj   +1 more source

Association of Heel Bone Mineral Density With Incident Disability and Mortality in Community‐Dwelling Older Adults

JBMR Plus, 2020
Age‐related bone loss is common in older adults. However, the association of low bone mass with incident disability and mortality is not well established.
Ryan D Ross, Raj C Shah, Sue E Leurgans, Aron S Buchman, David A Bennett   +4 more
doaj   +1 more source

Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation

iScience, 2021
Summary: It has been suggested that aberrant activation of glycogen synthase kinase-3-beta (GSK-3β) can trigger abnormal tau hyperphosphorylation and aggregation, which ultimately leads to neuronal/synaptic damage and impaired cognition in Alzheimer ...
Ana Claudia Amaral, Beatriz G. Perez-Nievas, Michael Siao Tick Chong, Alicia Gonzalez-Martinez, Herminia Argente-Escrig, Sara Rubio-Guerra, Caitlin Commins, Serra Muftu, Bahareh Eftekharzadeh, Eloise Hudry, Zhanyun Fan, Prianca Ramanan, Shuko Takeda, Matthew P. Frosch, Susanne Wegmann, Teresa Gomez-Isla   +15 more
doaj  

Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231.
Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco   +27 more
doaj   +1 more source

T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress.
Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group   +15 more
doaj   +1 more source

Plasma p‐tau217 concordance with amyloid PET among ethnically diverse older adults

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Commercially available plasma p‐tau217 biomarker tests are not well studied in ethnically diverse samples. METHODS We evaluated associations between ALZPath plasma p‐tau217 and amyloid‐beta positron emission tomography (Aβ‐PET) in Hispanic ...
Breton M. Asken, Jesse C. DeSimone, Wei‐En Wang, Karen N. McFarland, Franchesca Arias, Shellie‐Anne Levy, Jacob Fiala, Idaly Velez‐Uribe, Robin P. Mayrand, Luana Okino Sawada, Christian Freytes, Michael Adeyosoye, Warren W. Barker, Elizabeth A. Crocco, Steven T. DeKosky, Malek Adjouadi, Monica Rosselli, Michael Marsiske, Melissa J. Armstrong, Glenn E. Smith, Rosie Curiel Cid, David A. Loewenstein, David E. Vaillancourt, Ranjan Duara   +23 more
doaj   +1 more source

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Introduction Neurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer's disease. We test whether t‐tau and alternative biomarkers of neurodegeneration—neurogranin and neurofilament light protein (NFL)—add ...
Andrew P. Merluzzi, Nicholas M. Vogt, Derek Norton, Erin Jonaitis, Lindsay R. Clark, Cynthia M. Carlsson, Sterling C. Johnson, Sanjay Asthana, Kaj Blennow, Henrik Zetterberg, Barbara B. Bendlin   +10 more
doaj   +1 more source

Comprehensive Review on Alzheimer’s Disease: Causes and Treatment

Molecules, 2020
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities.
Zeinab Breijyeh, R. Karaman
semanticscholar   +1 more source